FLIXODERM ® Fluticasone

FLIXODERM ® is a Fluticasone propionate based drug.

THERAPEUTIC GROUP: Non-associated corticosteroids

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications FLIXODERM ® Fluticasone

FLIXODERM ® is indicated for the treatment of dermatological inflammatory diseases sensitive to treatment with corticosteroids.

FLIXODERM ® Fluticasone mechanism of action

FLIXODERM ® is a medicinal product based on Fluticasone propionate, a particularly active corticosteroid and therefore with a generally higher therapeutic index than other topical corticosteroids.

Applied topically, it is evenly distributed among the various cell layers of the epidermis, carrying out its own therapeutic action through the inhibition of the synthesis of inflammatory mediators, the inhibition of the recruitment of inflammatory cells, the blocking of bound enzymatic events. to the development of the inflammatory lesion.

All this results in the reduction of edema, redness and the classic symptomatology present during dermatological inflammatory pathologies, thus guaranteeing a clear and striking improvement in the clinical picture.

The modest systemic absorption of the active principle that occurs after the use of FLIXODERM ® makes the therapy generally safe and free of clinically significant side effects.

Studies carried out and clinical efficacy

THE EFFECTS OF FLUTICASONE ON THE FLAMMED PULMONARY MATRIX

Am J Physiol Lung Cell Mol Physiol. 2013 Aug 30. [Epub ahead of print]

Very interesting molecular study that tests the biological effects of Fluticasone on the pulmonary matrix of patients with severe chronic obstructive pulmonary disease, highlighting the ability of this drug to remodulate the expression of collagen and proteoglycans, normalizing the whole.

FLUTICASONE IN ASTHMA TREATMENT

Acta Otolaryngol. 2013 Sep; 133 (9): 939-43. doi: 10.3109 / 00016489.2013.783715.

Study demonstrating how the addition of fluticasone propionate to nasal drops can guarantee an improvement in respiratory capacity in patients suffering from nasal polyposis with asthma.

FLUTICASONE AND ALLERGIC RHINITIS

Ann Allergy Asthma Immunol. 2013 Jul; 111 (1): 45-50. doi: 10.1016 / j.anai.2013.04.013. Epub 2013 May 12.

Yet another study that demonstrates the effectiveness of Fluticasone in the treatment of respiratory difficulties in patients with perennial allergic rhinitis, highlighting a marked improvement in symptoms in the face of side effects of little clinical relevance.

Method of use and dosage

FLIXODERM ®

Cream for cutaneous use with 0.05% Fluticasone propionate;

Ointment at 0.005% of Fluticasone propionate.

The precise definition of the dosing schedule and the type of pharmaceutical format is the responsibility of the physician after carefully evaluating the patient's health conditions and the severity of his clinical picture.

In principle, the application of the appropriate quantity of medicine once or twice a day, directly on the area affected by the inflammatory process, is sufficient to guarantee a prompt remission of the symptomatology.

Warnings FLIXODERM ® Fluticasone

FLIXODERM ® therapy must necessarily be preceded by a careful medical examination in order to assess the extent of the lesions and any prescriptive appropriateness.

Given the biological potency of Fluticasone the use of this drug should be carried out with particular caution and always under medical supervision in patients suffering from psoriasis, renal insufficiency, liver failure, in elderly and pediatric patients.

The presence of excipients such as cetostearyl alcohol and propylene gilcole could significantly increase the risk of local allergic manifestations.

It is also useful to remember that the occurrence of side effects correlates perfectly with the duration of the therapy and with the dosages used.

PREGNANCY AND BREASTFEEDING

The use of FLIXODERM ® is generally contraindicated during pregnancy and in the subsequent period of breastfeeding, given the absence of clinical trials able to better characterize the safety profile of Fluticasone for the health of the fetus and infant.

Interactions

At the present time, known pharmacological interactions are not known, although it should be remembered that the simultaneous intake of cytochrome inhibitor drugs may increase blood concentrations of the amount of corticosteroid absorbed.

Contraindications FLIXODERM ® Fluticasone

The use of FLIXODERM ® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients, in patients with lesions associated with inadequately treated viral, bacterial and fungal infections, rosacea, perioral dermatitis and genital itching.

Undesirable effects - Side effects

The use of FLIXODERM ®, especially if continued for a long time, could determine the appearance of local adverse reactions such as redness, burning, folliculitis, hypertrichosis, rash, hypopigmentation and skin atrophy.

Fortunately, the incidence of potential systemic side effects is rarer.